Product Description
GSK is developing GSK-5764227, an ADC-targeting B7-H3 for treatment of solid tumors. (Sourced from: https://www.gsk.com/media/11102/q1-2024-pipeline-assets-and-clinical-trials-report.pdf)
Mechanisms of Action: B7-H3 Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|